Close menu




June 18th, 2021 | 09:56 CEST

Adler Modemärkte, Steinhoff, Osino Resources: Which penny stocks have substance?

  • Investments
Photo credits: pixabay.com

Penny stocks often have something disreputable about them - at least in Germany. As soon as a share is quoted at less than EUR 1 in Germany, it is considered to be at risk of insolvency. The reason for this is that the minimum nominal value of German stock corporations is EUR 1. Abroad, however, things are quite different: In Australia, it is not uncommon for shares to trade even below one cent. For investors who are used to this, it is anything but disreputable. In concrete terms, it all depends on the companies themselves anyway. We profile three companies that are either penny stocks or were, not long ago.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE000A1H8MU2 , NL0011375019 , CA68828L1004

Table of contents:


    Adler Modemärkte: Will the restart work?

    The shares of Adler Modemärkte have been hyped mightily in recent weeks. There was a reason for this: the Company slid into planned insolvency in the wake of the lockdowns. Most recently, there were good reasons to believe that the fashion chain will continue its business. The Company received an emergency loan of EUR 10 million and resumed delivering goods to its stores. Adler wants to find an investor by mid-June and then start restructuring the Company. That could be crowned with success. Adler Modemärkte has always tended to have older customers. According to optimistic market participants, the boom in online retailing could have less of an impact on the Company after the crisis than with young fashion chains.

    On the other hand, an unsuccessful search for an investor could further exacerbate employees' and investors' fears for the future. Most recently, the stock came back significantly and even tested the EUR 1 mark. The share is still nothing more than a hot gamble. However, after the recent price losses, a rise could soon be imminent. How sustainable this will be, however, depends on the restructuring of the Company.

    Steinhoff: What will become of the gamblers' darling?

    The situation at furniture manufacturer Steinhoff is even more complicated than Adler's. While Steinhoff is not in insolvency proceedings, the stock's success depends on a complex legal process. After Steinhoff was involved in an accounting scandal, shareholders are demanding money from the Company. The legal battle has been going on for years. The stock plunged in the wake of the threat of over-indebtedness following a possible ruling. The hopes of many gamblers rest on a possible settlement between the plaintiffs and Steinhoff.

    In recent months, interim results and other water level reports surrounding the pending settlement have repeatedly caused the stock to twitch. Since the Steinhoff share is currently trading at EUR 0.11, investors can quickly gain 10 or 20%. In the same way, however, the price can also crash. Nothing has been happening with the share for weeks. For many private investors, the speculation has probably come to nothing. A new investment does not offer itself meanwhile: Who wants to invest in a legal dispute?

    Osino Resources: Promising gold project instead of principle hope

    Unlike Adler Modemärkte and Steinhoff, the Canadian Company Osino Resources has no problems - rather the opposite. The Company is looking for gold in Namibia and is active there in the well-known Damara mineral belt. There are already producing gold mines in the neighborhood. One of these mines, B2Gold's Otjikoto mine, was discovered by the team around Osino CEO Heye Daun himself and ultimately sold to the mining giant. So Osino Resources is operating in a known area and has already proven how to explore and develop resource properties until they can either be put into production or sold.

    The Osino Resources share was a penny stock in Germany just a few weeks ago. In the meantime, however, that has changed. Osino CEO Daun emphasizes that his Twin Hills project can make rapid progress. The geological parallels between Osino Resources' exploration project and the geology of the Otjikoto mine, already in production, are striking. (Read the Interview with CEO Heye Daun for more on this.) This view is also becoming more widely accepted in the market. Unlike many penny stocks, Osino Resources has a clear strategy, a promising project and convinced investors, such as mining legend Ross Beaty. Osino Resources' opportunities are likely to be significantly greater than those of companies in insolvency proceedings or litigation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read